Etofylline

• UNSPSC Description:

  Etofylline (7-(β-Hydroxyethyl) theophylline) is an oral bronchodilator with anti-inflammatory effects. Etofylline inhibits phosphodiesterase and prevents the degradation of cAMP (cyclic adenosine monophosphate), leading to smooth muscle relaxation, reducing inflammatory responses and improving respiratory function. Etofylline affects the development of zebrafish embryos[1][2][3].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Etofylline.html

• Purity:

  99.72

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(N1C)N(C)C2=C(N(CCO)C=N2)C1=O

• Molecular Weight:

  224.22

• References & Citations:

  [1]Wattanaporn Tavipatana, et al.Etophylline and theophylline pharmacokinetics when administered concomitantly in rabbits. International Journal of Pharmaceutics. Volume 30, Issues 2–3|[2]Chandrakantsing V Pardeshi ,et al. Mannose-anchored N,N,N-trimethyl chitosan nanoparticles for pulmonary administration of etofylline. Int J Biol Macromol. 2020 Dec 15;165(Pt A):445-459.|[3]Ram Manohar Basnet, et al. Zebrafish Embryo as an In Vivo Model for Behavioral and Pharmacological Characterization of Methylxanthine Drugs. Int J Mol Sci. 2017 Mar 9;18(3):596.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  519-37-9